Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3(TM) LVAD

Stock Information for Cadrenal Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.